Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME of [14C] AC0010 in Advanced NSCLC
NCT03001609Phase 1Completed
- Sponsor
- ACEA Therapeutics
- Start
- Nov 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abivertinib in non-small cell lung cancer (NSCLC), sponsored by ACEA Therapeutics. Primary endpoint: Pharmacokinetics, Cumalative excretion and Metabolite of 14C-labeled AC0010 at 8 Days. Started Nov 2016; status: completed.
02
Drugs
abivertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03001609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03001609.